APEX1 and non-small cell lung carcinoma: To determine the correlation between serum APE1-AAbs level and therapeutic response, the APE1-AAbs levels between pre- and post-chemotherapy were analyzed in 91 NSCLC patients who received 2 cycles of platinum-based regimen.